CN101804076A - Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation - Google Patents
Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation Download PDFInfo
- Publication number
- CN101804076A CN101804076A CN201010150787A CN201010150787A CN101804076A CN 101804076 A CN101804076 A CN 101804076A CN 201010150787 A CN201010150787 A CN 201010150787A CN 201010150787 A CN201010150787 A CN 201010150787A CN 101804076 A CN101804076 A CN 101804076A
- Authority
- CN
- China
- Prior art keywords
- atrial fibrillation
- chinese medicine
- combined
- hirudo
- cerebral thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation, which belongs to the technical field of medicines. The traditional Chinese medicine is prepared by leech, Hirudinaria manillensis, blood sucker or composite thereof, and can be clinically used for treating cerebral thrombosis combined with atrial fibrillation and made into capsules, tablets and pills according to conventional procedures.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, particularly relate to a kind of Chinese medicine preparation and preparation method that is used for the treatment of cerebral thrombosis combined with atrial fibrillation.
Background technology:
Cerebral embolism is the common type of cerebrovascular disease, onset is anxious, severe symptoms, the case fatality rate height, even stock, leave over handicap more, the commonly encountered diseases of cerebral embolism is because of because atrial fibrillation, account for 60%-75%, atrial fibrillation causes that easily cerebral embolism takes place repeatedly, so the recurrence of prevention of brain thromboembolism is important treatment measure, in recent years Chang Yong Western medicine such as warfarin or aspirin, because of risk, detection coagulation function and the intestinal side effect regularly that causes bleeding arranged, the patient is unwilling to accept generally speaking, is restricted so use clinically.Leeches animal Hirudo, Hirudinaria manillensis, cattle trematodiasis are natural direct thrombin inhibitors, its main active is a hirudin, it is the medicine of Chinese medicine treating blood disorders, studies show that hirudin is the Acid polypeptide that 65 amino acid residues are formed that contains of Hirudo salivary gland secretion, it is the thrombin inhibitor of high special, can stop Fibrinogen and fibrinous solidifying, also can suppress platelet and receive the release of stimulated by thrombin and make thrombin and the platelet disassociation.And leeches animal Hirudo, Hirudinaria manillensis, cattle trematodiasis or its extract for treating cerebral embolism merging atrial fibrillation have certain curative effect, and existing anticoagulant has the antiplatelet dual function again, and few side effects is fit to patient's life-time service, effectively prevention of brain thromboembolism recurrence.It has opened up a kind of new means to the treatment that cerebral embolism merges atrial fibrillation.
Summary of the invention
The objective of the invention is to be clinical Chinese medicine that a kind of effective treatment cerebral thrombosis combined with atrial fibrillation is provided and preparation method thereof.
The present invention is achieved through the following technical solutions:
Chinese medicine preparation of the present invention is by being to be made by Hirudo, Hirudinaria manillensis, Hirudo or its combination.
Manufacturing method for above mentioned medicine is: Hirudo, Hirudinaria manillensis, Hirudo silt are cleaned, clear water is hungry raised 5-15 days, freezing in-10～30 ℃, tissue mashing machine's system homogenate, dry below 50 ℃, be ground into fine powder, add suitable adjuvant, make capsule, tablet, drop, pill according to conventional operation.
Can effectively treat the patient of cerebral thrombosis combined with atrial fibrillation on the clinical drug of the present invention, and have no side effect.
Experimental example one pharmacodynamic experiment
Pharmaceutical preparation main pharmacodynamics result of study of the present invention has confirmed that this pharmaceutical composition has the effect of stronger treatment cerebral thrombosis combined with atrial fibrillation.
1 materials and methods
1.1 object of study: type cerebral embolism companion patients with atrial fibrillation 120 examples of selecting Neurology Department clinically to be in hospital, age 33-62 year, male 70 examples, women 30 examples, diagnosis of cerebral infarction all meets the diagnostic criteria of the 4th the cerebrovascular meeting revision in the whole nation, all confirms through CT or MRI.Include standard in: be diagnosed as cerebral embolism and merge atrial fibrillation.The discharge standard: (1) intracranial tumor, serious hepatic and renal function injure, blood are disease, digestive tract hemorrhage and the patient that sickens for consciousness; (2) acute myocardial infarction, unstable angina pectoris, hyperthyroidism, gestation, electrolyte disturbance; (3) drug allergy person.
1.2 all patients of research method are admitted to hospital and the clinical neurologic deficit of stroke patients degree standards of grading of all formulating according to the 4th the cerebrovascular academic conference in the whole nation 1 month time the (CNFDS) of falling ill are marked, as of judging prognosis.All patients all give the intravenous injection XUESAITONG ZHUSHEYE and citicoline is Primary Care simultaneously.
All patients are divided into two groups at random, pharmaceutical preparation group (A group) 70 examples, warfarin group (B group) 30 examples.CNFDS scoring there was no significant difference has comparability before two groups of patient ages, sex, protopathy, the patient treatment.Wherein A organizes with pharmaceutical preparation (Guizhou letter nation pharmacy institute of materia medica provides capsule) 750mg/ time, 3 times/day.The B group 1 time/day, is looked the slow dosage of patients Wits with warfarin (Group Co.,Ltd produces by Shanghai medicine) initial amount 2.5mg.Two groups of patients all complete successfully Drug therapy January.All patients give blood, urine routine test, hepatic and renal function, electrocardiogram, coagulation function, hemorheology inspection.Record curative effect and side effect.
1.3 efficacy determination
When judging according to patient treatment, prognosis the Patients with Cerebral Infarction recent prognosis is divided into 4 grades with the CNFDS scoring number of morbidity during January; (1) marked improvement: morbidity during January the CNFDS scoring improve at 50%-99% or recover normal fully; (2) progressive: the CNFDS scoring improves at 16%-49% when falling ill January; (3) no change: morbidity during January the CNFDS scoring improve below 15% or do not have a recovery; (4) death.Marked improvement and progress are good prognosis, and no change and death are poor prognosis.
1.4 statistical procedures X2 check.
2 results
2.1 therapeutic effect treatment group: marked improvement 41 examples, progressive 25 examples, no change 4 examples, dead 0 example.Matched group: marked improvement 14 examples, progressive 13 examples, no change 2 examples, dead 1 example. two groups of patient's total effective rates have significant difference (P＜0.05), and the treatment group is better than matched group.
2.2 the scoring of treatment neurological functional deficit changes relatively, see Table 1. liang of group onlookers and treat preceding neurological functional deficit diversity of values not statistically significant (P＞0.05), after treating January, two groups of patient's neurological functional deficit scorings all obviously reduce, neurologic impairment all has obvious recovery (P＜0.05), and pharmaceutical preparation group neurologic impairment recovers significantly better than warfarin group (P＜0.05).
The scoring of table 1 neurological functional deficit changes relatively
Annotate: neurological deficits score compares before and after the treatment, P＜0.05, and treatment back A group is organized relatively P＜0.05 of neurological deficits score with B.
2.3 two groups of patient's recent prognosis relatively, sees Table 2. treatments through January, pharmaceutical preparation group recent prognosis is better than warfarin group (P＜0.05).
The table 2 liang back recent prognosis comparison of group case treatment (example, %)
Annotate: the A group compares P＜0.05 with the prognosis of B group.
2.4 untoward reaction pharmaceutical preparation group does not have obvious adverse reaction.Subcutaneous ecchymosis appears in warfarin group 3 examples, and 2 routine gingivas are begun to learn, but not serious, do not influence medication.Two groups of blood, routine urinalysis, hepatic and renal function inspection, difference does not have significance before and after the treatment.
3 discuss
Use 70 routine cerebral embolism patients of pharmaceutical preparation group treatment, total effective rate reaches 94.2%, and marked improvement and progressive joint account treatment group are better than matched group, and significant significant difference is arranged.Check hepatic and renal function and coagulation function were normal after treatment finished.There are blood fat and the blood viscosity person of increasing to drop to normal range before the medication.Point out this pharmaceutical preparation can effectively reduce blood fat and blood viscosity.In therapeutic process, do not find side effect such as mucocutaneous spontaneous ecchymosis, gingival hemorrhage and digestive tract hemorrhage, this pharmaceutical preparation treatment cerebral embolism of this research prompting merges atrial fibrillation curative effect preferably, existing anticoagulant, the antiplatelet dual function is arranged again, few side effects, be fit to patient's life-time service, effectively prevention of brain thromboembolism recurrence.
Embodiment 1
Hirudo (live body)
Method for making: water intaking trematodiasis live body, silt is cleaned, clear water is hungry raised 5 days, in-15 ℃ freezing, tissue mashing machine's system homogenate, dry below 50 ℃, be ground into fine powder, encapsulated, make every to contain the Hirudo live body and must not be less than 0.25g, promptly.
Embodiment 2
Hirudo (live body) Hirudo (live body)
Method for making: water intaking trematodiasis, Hirudo live body, silt is cleaned, and clear water is hungry raised 5 days, freezing in-30 ℃, tissue mashing machine's system homogenate, dry below 50 ℃, be ground into fine powder, add proper auxiliary materials tabletting, coating, make every to contain the Hirudo live body and must not be less than 0.25g, promptly.
Embodiment 3
Hirudo (live body) Hirudinaria manillensis (live body)
Method for making: water intaking trematodiasis, Hirudo live body, silt is cleaned, clear water is hungry raised 15 days, in-10 ℃ freezing, tissue mashing machine's system homogenate, dry below 50 ℃, be ground into fine powder, pill, coating below 50 ℃ make every ball contain the Hirudo live body and must not be less than 0.25g, promptly.
Claims (3)
1. a Chinese medicine preparation that is used for the treatment of cerebral thrombosis combined with atrial fibrillation is characterized in that being made by Hirudo, Hirudinaria manillensis Hirudo or its combination.
2. the preparation method of Chinese medicine preparation according to claim 1 is: Hirudo, Hirudinaria manillensis, Hirudo silt are cleaned, clear water is hungry raised 5-15 days, freezing in-10～30 ℃, tissue mashing machine's system homogenate, dry below 50 ℃, be ground into fine powder, add suitable adjuvant, make capsule, tablet, pill according to conventional operation.
3. according to the application of the described Chinese medicine composition of claim 1-2 in the medicine of preparation treatment cerebral thrombosis combined with atrial fibrillation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010150787A CN101804076A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010150787A CN101804076A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101804076A true CN101804076A (en) | 2010-08-18 |
Family
ID=42606136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010150787A Pending CN101804076A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101804076A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953852A (en) * | 2010-09-16 | 2011-01-26 | 贵州信邦制药股份有限公司 | Antithrombin preparation and preparation method thereof |
-
2010
- 2010-04-20 CN CN201010150787A patent/CN101804076A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953852A (en) * | 2010-09-16 | 2011-01-26 | 贵州信邦制药股份有限公司 | Antithrombin preparation and preparation method thereof |
| CN101953852B (en) * | 2010-09-16 | 2014-09-24 | 贵州信邦制药股份有限公司 | Antithrombin preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105213971A (en) | Treat psoriatic Chinese medicine composition | |
| KR101519899B1 (en) | Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction | |
| CN102462825B (en) | Compound traditional Chinese medicine for treating depression | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN102631526A (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN107648479A (en) | A kind of Chinese prescription and its product for being used to treat hypertension | |
| CN101804076A (en) | Traditional Chinese medicine preparation used for treating cerebral thrombosis combined with atrial fibrillation | |
| CN109223995A (en) | A kind of pharynx-clearing throat-benefiting Traditional Chinese medicine lozenge | |
| CN102145050A (en) | Application of traditional Chinese medicine composition for preparing drugs for preventing and treating post percutaneous coronary intervention (PCI) no-reflow | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN110354193B (en) | Traditional Chinese medicine compound composition for treating anovulatory infertility and application thereof | |
| CN108272949B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating dementia | |
| CN101618204A (en) | Medicine composition for treating cold of insufficiency type and stomachache and preparation method thereof | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN101579482B (en) | Medicinal composition for treating hypertension and preparation method thereof | |
| CN114404535B (en) | Pharmaceutical composition for relieving cancer-induced fatigue and chronic fatigue syndrome, and preparation method and application thereof | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| TW201900195A (en) | Herbal composition for preventing or alleviating ischemic stroke | |
| CN101632728B (en) | Application of Chinese medicinal composition in preparing medicament for protecting blood brain barrier | |
| CN101773494A (en) | New application of green tea polyphenol | |
| CN104173496A (en) | Application of Xinkeshu preparation in preparing medicine for treating hypertension with coronary heart disease with accompany of anxiety and mental depression problems and preparation method of Xinkeshu preparation | |
| CN101269142B (en) | Application of Chinese medicinal composition in preparing medicament for treating right bundle branch conduction block | |
| CN107233430B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN103690555A (en) | Pharmaceutical composition for treating acetyl cholinergic urticaria | |
| CN104758759B (en) | Application of the Chinese medicine composition in the drug of preparation treatment Chronic Obstructive Pulmonary Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100818 |